Showing 981-990 of 1093 results for "".
- Updates on Aesthetic Meeting Cancellations Due to COVID-19https://modernaesthetics.com/news/aesthetic-meeting-cancellation-updates/2472895/In an attempt to help slow the continuing spread of the COVID-19 virus, many industry societies have cancelled or postponed conferences. The Aesthetics Meeting 2020 has postponed its meeting, which was scheduled to start on April 25 in Las Vegas. Find more inforamtion about the postpone
- Meet Zaffiro, Neauvia’s Two-Part Solution to Skin Rejuvenationhttps://modernaesthetics.com/news/meet-zaffiro-neuvias-two-part-solution-to-skin-rejuvenation/2472893/Neauvia introduced Zaffiro to the media at an event held in New York City’s Hudson Yards, featuring New York City dermatologist Amy Lewis, MD Launched in the US in late 2019, the Zaffiro device is a dual facial rejuvenation system combining wa
- BTL Suit Alleges False Advertising by Allerganhttps://modernaesthetics.com/news/btl-suit-alleges-false-advertising-by-allergan-1/2472885/In a new lawsuit filed this week, BTL Industries alleges that Allergan launched a wide-ranging false and misleading advertising campaign relating to BTL's EMSCULPT device for non-invasive muscle toning and body shaping. The suit alleges that Allergan's marketing, sales materials, and soci
- Get Ready for Allergan's New DTC Juvéderm Lips Campaignhttps://modernaesthetics.com/news/get-ready-for-allergans-new-dtc-juvederm-lips-campaign/2472882/Allergan is launching its new direct-to-consumer campaign for Juvéderm lips with ads and creative deploying across TV, social media, and digital advertising. As part of the new campaign, New York City-based facial plastic surgeon Dara Liotta, MD, reality television personality Au
- FDA Sets November PDUFA Date for DaxibotulinumtoxinA from Revancehttps://modernaesthetics.com/news/fda-sets-november-pdufa-date-for-daxibotulinumtoxina-from-revance/2472880/FDA has accepted the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar (frown) lines, Revance reports. The FDA set an action date of November 25, 2020 under the Prescription Drug User Fee Act (PDUFA) VI program.
- Candela Launches Exceed Medical Microneedling Systemhttps://modernaesthetics.com/news/candela-launches-exceed-medical-microneedling-system/2472878/Candela Corporation has entered into an exclusive collaboration agreement with MT.DERM GmbH for the commercialization of MT.DERM's medical microneedling products. Under the terms of the agreement, Candela will commercialize the Exceed medical microneedling system globally, with a first launch
- SkinMedica's DiamondGlow Hits Doctor's Officeshttps://modernaesthetics.com/news/skinmedicas-diamondglow-hits-doctors-offices/2472875/llergan’s Skinmedica is rolling out DiamondGlow, a non-invasive dermabrasion technology that exfoliates, extracts, and treats the face, eye area, lips and body. Allergan acquired Envy Medical, Inc and its Silkpeel&nbs
- Most Plastic Surgery YouTube and Social Media Videos Are Poor Qualityhttps://modernaesthetics.com/news/most-plastic-surgery-youtube-and-social-media-videos-are-poor-quality/2472874/YouTube and social media videos aren't necessarily the most reliable source of plastic surgery information, concludes a study in the February issue of Plastic and Reconstructive Surgery. Despite this, a recent American So
- Cynosure News: Todd Tillemans Named New CEOhttps://modernaesthetics.com/news/cynosure-news-todd-tillemans-named-new-ceo/2472869/Todd Tillemans is the new Chief Executive Officer of Cynosure, LLC. Mr. Tillemans is the former President of Hershey's flagship U.S. business generating more than $6.5 billion in annual sales. Prior to that, he held various leadership positions across Unilever's
- New Data from Revian Red: System Shown to Support Hair Growthhttps://modernaesthetics.com/news/new-data-from-revian-red-system-shown-to-support-hair-growth/2472868/The Revian Red hair growth system demonstrates the ability to successfully stop hair loss and subsequently grow new hair, according to final data from a randomized, double-blind study. Findings were presented at the 2020 Winter Clinical Dermatology Conference – Hawaii an